{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:47:12Z","timestamp":1791362832303,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00467-023-05927-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:26:39Z","timestamp":1679862399000},"page":"3483-3487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis"],"prefix":"10.1007","volume":"38","author":[{"given":"Magdalena","family":"Riedl Khursigara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tjon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Chami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-0799","authenticated-orcid":false,"given":"Chia Wei","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"5927_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","volume":"32","author":"M Riedl","year":"2017","unstructured":"Riedl M, Thorner P, Licht C (2017) C3 Glomerulopathy. Pediatr Nephrol 32:43\u201357. https:\/\/doi.org\/10.1007\/s00467-015-3310-4","journal-title":"Pediatr Nephrol"},{"key":"5927_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.ekir.2020.09.019","volume":"5","author":"A Kirpalani","year":"2020","unstructured":"Kirpalani A, Jawa N, Smoyer WE et al (2020) Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children. Kidney Int Rep 5:2313\u20132324. https:\/\/doi.org\/10.1016\/j.ekir.2020.09.019","journal-title":"Kidney Int Rep"},{"key":"5927_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ekir.2017.08.019","volume":"3","author":"R Chanchlani","year":"2018","unstructured":"Chanchlani R, Thorner P, Radhakrishnan S et al (2018) Long-term eculizumab therapy in a child with refractory immune complex-mediated membranoproliferative glomerulonephritis. Kidney Int Rep 3:482\u2013485. https:\/\/doi.org\/10.1016\/j.ekir.2017.08.019","journal-title":"Kidney Int Rep"},{"key":"5927_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","volume":"74","author":"P Ruggenenti","year":"2019","unstructured":"Ruggenenti P, Daina E, Gennarini A et al (2019) C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial. Am J Kidney Dis 74:224\u2013238. https:\/\/doi.org\/10.1053\/j.ajkd.2018.12.046","journal-title":"Am J Kidney Dis"},{"key":"5927_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMc1111953","volume":"366","author":"M Vivarelli","year":"2012","unstructured":"Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163\u20131165. https:\/\/doi.org\/10.1056\/NEJMc1111953","journal-title":"N Engl J Med"},{"key":"5927_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","volume":"72","author":"M Le Quintrec","year":"2018","unstructured":"Le Quintrec M, Lapeyraque A-L, Lionet A et al (2018) Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72:84\u201392.\u00a0https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.019","journal-title":"Am J Kidney Dis"},{"key":"5927_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"key":"5927_CR8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2215\/CJN.00320116","volume":"11","author":"S Tellier","year":"2016","unstructured":"Tellier S, Dallocchio A, Guigonis V et al (2016) Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 11:1777\u20131782. https:\/\/doi.org\/10.2215\/CJN.00320116","journal-title":"Clin J Am Soc Nephrol"},{"key":"5927_CR9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233\u20131243. https:\/\/doi.org\/10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"key":"5927_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A et al (2020) Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab. Blood 135:1049\u20131057. https:\/\/doi.org\/10.1182\/blood.2019004218","journal-title":"Blood"},{"key":"5927_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cei.12890","volume":"187","author":"C Wehling","year":"2017","unstructured":"Wehling C, Amon O, Bommer M et al (2017) Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 187:304\u2013315. https:\/\/doi.org\/10.1111\/cei.12890","journal-title":"Clin Exp Immunol"},{"key":"5927_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, ter Heine R, Moes DJAR et al (2019) Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet 58:859\u2013874. https:\/\/doi.org\/10.1007\/s40262-019-00742-8","journal-title":"Clin Pharmacokinet"},{"key":"5927_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/cpt.686","volume":"102","author":"E Volokhina","year":"2017","unstructured":"Volokhina E, Wijnsma K, van der Molen R et al (2017) Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther 102:671\u2013678. https:\/\/doi.org\/10.1002\/cpt.686","journal-title":"Clin Pharmacol Ther"},{"key":"5927_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5414\/CN109583","volume":"91","author":"A Kirpalani","year":"2019","unstructured":"Kirpalani A, Rothfels L, Sharma AP et al (2019) Nephrotic state substantially enhances apparent mycophenolic acid clearance. Clin Nephrol 91:162\u2013171. https:\/\/doi.org\/10.5414\/CN109583","journal-title":"Clin Nephrol"},{"key":"5927_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RES Bullingham","year":"1998","unstructured":"Bullingham RES, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429\u2013455. https:\/\/doi.org\/10.2165\/00003088-199834060-00002","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-05927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-05927-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-05927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T14:07:09Z","timestamp":1693318029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-05927-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5927"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-05927-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent was obtained from the parent of the patient for publication of the case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of conflicts of interest"}}]}}